Assignee
POXEL SA
FR12 patents
Top patents by PatentIndex Score
US10940143B2Mar 9, 2021
Deuterium-enriched pioglitazone
POXEL SA1 citations73
US11123336B2Sep 21, 2021
5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
POXEL SA2 citations71
US10265305B2Apr 23, 2019
5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
POXEL SA2 citations71
US11918567B2Mar 5, 2024
Deuterium-enriched pioglitazone
POXEL SA0 citations62
US11617754B2Apr 4, 2023
Methods of treating heart failure with preserved ejection fraction
POXEL SA0 citations61
US11918569B2Mar 5, 2024
5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
POXEL SA0 citations60
US11141411B2Oct 12, 2021
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
POXEL SA0 citations60
US11319313B2May 3, 2022
Crystalline forms of deuterium-enriched pioglitazone
POXEL SA0 citations54
US10576071B2Mar 3, 2020
Deuterium-enriched pioglitazone
POXEL SA0 citations52
US12036226B2Jul 16, 2024
Methods of treating subjects having diabetes with chronic kidney disease
POXEL SA0 citations49
US11266652B2Mar 8, 2022
Methods of treating subjects having diabetes with chronic kidney disease
POXEL SA0 citations47
US11767317B1Sep 26, 2023
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
POXEL SA0 citations44